IGF1 and plasma cell myeloma: Therefore, given our demonstration that IGF-1 confers resistance to combined trametinib and dexamethasone, it was possible that the synergistic effects observed in myeloma cells cultured in vitro may be blunted in vivo due to signalling cues from the supporting stroma.